Presentation is loading. Please wait.

Presentation is loading. Please wait.

Allergen-specific immunotherapy with recombinant grass pollen allergens  Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Published byΔημοσθένης Θεοτόκης Modified over 5 years ago

Similar presentations

Presentation on theme: "Allergen-specific immunotherapy with recombinant grass pollen allergens  Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,"— Presentation transcript:

1 Allergen-specific immunotherapy with recombinant grass pollen allergens 
Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math, Helmut Fiebig, PhD, Oliver Cromwell, PhD  Journal of Allergy and Clinical Immunology  Volume 116, Issue 3, Pages (September 2005) DOI: /j.jaci Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

2 Fig 1 Symptom scores, medication scores, and symptom-medication scores (SMS) (per protocol set). Evaluation based on a 42-day period encompassing the main pollen exposure, starting 15 days before and ending 26 days after the day with the maximum pollen count. Median values with 25th, 75th (boxes), 10th, and 90th (error bars) percentiles, and outliers (points). A, Active treatment (gray bars); P, placebo treatment (white bars). Mann-Whitney U test. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

3 Fig 2 Rhinitis quality of life questionnaire: differences between the means for the 2 treatment groups in the first and second year (full analysis set). The questionnaires completed following the maximum pollen counts in 2002 (gray bars) and 2003 (black bars) were used for analysis. Mann-Whitney U test and P values for 2003 season. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

4 Fig 3 Grass pollen specific IgE, IgG1, and IgG4 antibody concentrations (full analysis set). Median values with 25th/75th and 10th/90th percentiles represented by boxes and error bars, respectively, and outliers by points. Active (gray bars) and placebo (white bars) groups. Time points: 1, before immunotherapy, 1/2002-2/2002; 2, after initial dosage increase and before pollen season, 4/2002-5/2002; 3, after the pollen season, 7/2002-9/2002; 4, after 12 months, 1/2003-3/2003; 5, before the pollen season, 4/2003-5/2003; 6, at the end of the study, 8/2003-9/2003. ∗∗∗P < .001; NS, nonsignificant. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Download ppt "Allergen-specific immunotherapy with recombinant grass pollen allergens  Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,"

Similar presentations

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy  Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy  Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

Similar presentations

Ads by Google